Disrupted Circadian Rhythms in a Mouse Model of Schizophrenia  by Oliver, Peter L. et al.
Disrupted Circadian RhythmCurrent Biology 22, 314–319, February 21, 2012 ª2012 Elsevier Ltd. Open access under CC BY license. DOI 10.1016/j.cub.2011.12.051Report
s
in a Mouse Model of SchizophreniaPeter L. Oliver,1,6 Melanie V. Sobczyk,2,6
Elizabeth S. Maywood,3 Benjamin Edwards,1 Sheena Lee,1
Achilleas Livieratos,1 Henrik Oster,4 Rachel Butler,2
Sofia I.H. Godinho,2 Katharina Wulff,2 Stuart N. Peirson,2
Simon P. Fisher,2,7 Johanna E. Chesham,3
Janice W. Smith,5,8 Michael H. Hastings,3 Kay E. Davies,1,*
and Russell G. Foster2,*
1MRC Functional Genomics Unit, Department of Physiology,
Anatomy and Genetics, University of Oxford, Parks Road,
Oxford OX1 3PT, UK
2Nuffield Laboratory of Ophthalmology, University of Oxford,
Levels 5 and 6 West Wing, John Radcliffe Hospital,
Headley Way, Oxford OX3 9DU, UK
3Division of Neurobiology, MRC Laboratory of Molecular
Biology, Hills Road, Cambridge CB2 0QH, UK
4Circadian Rhythms Group, Max Planck Institute for
Biophysical Chemistry, Am Fassberg 11, 37077 Gottingen,
Germany
5Lilly, Erl Wood Manor, Sunninghill Road, Windlesham,
Surrey GU20 6PH, UK
Summary
Sleep and circadian rhythm disruption has been widely
observed in neuropsychiatric disorders including schizo-
phrenia [1] and often precedes related symptoms [2].
However, mechanistic basis for this association remains un-
known. Therefore, we investigated the circadian phenotype
of blind-drunk (Bdr), a mouse model of synaptosomal-
associated protein (Snap)-25 exocytotic disruption that
displays schizophrenic endophenotypes modulated by
prenatal factors and reversible by antipsychotic treatment
[3, 4]. Notably, SNAP-25 has been implicated in schizo-
phrenia from genetic [5–8], pathological [9–13], and func-
tional studies [14–16].We showhere that the rest and activity
rhythms of Bdr mice are phase advanced and fragmented
under a light/dark cycle, reminiscent of the disturbed sleep
patterns observed in schizophrenia. Retinal inputs appear
normal in mutants, and clock gene rhythms within the
suprachiasmatic nucleus (SCN) are normally phased both
in vitro and in vivo. However, the 24 hr rhythms of arginine
vasopressin within the SCN and plasma corticosterone are
both markedly phase advanced in Bdr mice. We suggest
that the Bdr circadian phenotype arises from a disruption
of synaptic connectivity within the SCN that alters critical
output signals. Collectively, our data provide a link between
disruption of circadian activity cycles and synaptic dysfunc-
tion in a model of neuropsychiatric disease.6These authors contributed equally to this work
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Circadian wheel-running behavior in blind-drunk (Bdr) mu-
tants is markedly abnormal under light/dark (LD) conditions;
actograms showed an advanced circadian phasing, fragmen-
tation, and poor consolidation of nocturnal activity (Figure 1A).
Total activity levels of theBdrmice were reduced compared to
controls, and this can be attributed to the mild ataxia seen in
these animals (see Figure S1A available online). However,
there was a significant increase in light phase activity (19%
at 150 lux and 22% at 30 lux) during a 12 hr light/12 hr dark
(12:12 LD) schedule (Figure 1B). Reduced stability and
increased variability (Figures 1C and 1D) appear to underpin
circadian rhythm fragmentation and instability in Bdr mice
maintained under an LD cycle. Activity fragmentation is
demonstrated further in mutants by more frequent activity
bouts under LD (Figure S1B) with a decrease in periodogram
amplitude compared to littermates (Figure 1E). In addition,
the phase of entrainment was significantly advanced by
21.546 7.92min under a 150 lux LD cycle and particularly vari-
able under 30 lux dim LD in Bdr mice compared to controls
(Figures 1F and 1G). Heterogeneity in the locomotor behavior
of Bdr mice studied under a 12:12 LD cycle was marked,
with activity ranging from robust rhythms and entrained to
highly irregular profiles (Figure S1D). This range of circadian
phenotypes is similar to the heterogeneity observed in the
circadian rhythms of neuropsychiatric illness. Specifically,
abnormal phasing to the light/dark cycle, rest and activity
fragmentation, and circadian reversal have been reported
in schizophrenia [1, 17–20]; allowing for nocturnal versus
diurnal activity patterns, there are some notable parallels
between the Bdr and human circadian phenotypes as shown
(Figure S2).
To determine whether abnormalities in the light input to the
clock are modulating the Bdr phenotype, we exposed mice to
an acute phase shifting light pulse and a 6 hr LD cycle phase
advance (Figure S1C). The resulting phase shifting effects
were not significantly different between genotypes (Figures
2A and 2B). In addition, negative masking in Bdr mice was
comparable to controls (Figure 2C), suggesting that abnormal-
ities in the suppression of activity by light cannot account for
the Bdr phenotype. No differences were identified in gross
retinal anatomy (data not shown) or light-driven pupil constric-
tion in Bdr mice (Figure 2D) suggesting that abnormal inputs
from the eye are not the source of the circadian phenotype.
We also measured light induction of the immediate early
gene c-fos, and equivalent levels of expression were seen
in both Bdr and wild-type suprachiasmatic nucleus (SCN)
sections (Figures 2E and 2F), providing further evidence that
photic input to the SCN is not disrupted in mutant animals. A
summary of the behavioral screen parameters and the
complete set of circadian data are shown in Tables S1 and S2.
To address whether the circadian phenotype of the Bdr
mutant was an artifact of using running wheels, we undertook
24 hr home cage video tracking ofBdr and wild-typemice [21].
These data replicate the advanced phase of activity and the
negative masking previously observed by wheel running (Fig-
uresS3A–S3E). Additionally, estimations of total sleepduration
Figure 1. Bdr Mutants Display a Range of Circadian
Abnormalities
(A) Representative actograms of mouse running-wheel
activity counts (black bars displayed in 10 min bins)
show increased light activity (yellow panels) with less
consistent and shorter major activity periods inBdr com-
pared to controls under both 150 and 30 lux 12 hr LD
cycles.
(B) Based on wheel-running behavioral data, Bdr (Bdr/+)
mutants show increased light activity in LD and dim LD
compared to wild-type controls (+/+) (n = 9–12; p values:
LD = 0.0132, dim LD = 0.0226, analysis of variance
[ANOVA], planned comparison).
(C–G) LD rhythmicity showed that interdaily stability
(C) was also significantly reduced in Bdr animals (n =
11–12; p = 0.0011, t test) and intradaily variability (D)
was significantly increased in Bdr animals compared to
controls (n = 11–12; p = 0.0065, t test). Overall periodo-
gram amplitude was reduced in mutants under all
lighting conditions (E) (n = 8–12; p values: LD = 0.0027,
dim LD = 0.0004, constant darkness [DD] = 0.0061, and
lux constant light [LL] = 0.0075, ANOVA). Across both
LD conditions, entrainment is highly variable in the Bdr
cohort (F and G) and significantly earlier in the Bdr
animals under 150 lux LD (F) (n = 10–12, p = 0.0269,
ANOVA). Data are presented as mean 6 SEM. The full
data set and p values are summarized in Table S2.
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315[21] were not significantly different between genotypes
(Figure S3F).
To establish whether the Bdr phenotype might be related to
disruption of the core molecular clock, we undertook both
in vivo and in vitro approaches. Under constant conditions,
actograms were broadly similar and free-running circadianperiods (tau) were not significantly altered
between genotypes (Figures 3A and 3B).
SCN molecular rhythms were then exam-
ined in detail by crossing Bdr mice with a
Per2:Luciferase reporter strain. Consistent
with the behavioral findings under constant
conditions, we observed no significant differ-
ences in Per:Luc bioluminescence rhythms in
the SCN when compared to wild-type controls
(Figure 3C) or in recordings from the prefrontal
cortex and cerebellum (data not shown).
The data show that Bdrmice lack the ability
to maintain robust and appropriately phased
activity rhythms under LD cycles, whereas
their circadian locomotor behavior under con-
stant conditions is comparable to wild-type
littermates. Both retinal function and the
molecular clock appear normal. Collectively,
these observations suggested that the abnor-
mal phenotype of Bdr mice might be due to
defects in SCN outputs and the ability of the
SCN to regulate peripheral oscillations. To
address this issue, we undertook microarray
expression profiling from SCN-enriched tissue
punches across a 150 lux LD cycle from Bdr
and wild-type mice. Gene expression was
assessed during the mid-light phase (ZT6),
the late light phase (ZT11), and the early dark
phase (ZT13) when the most profound differ-
ences in locomotor activity were observed
between genotypes. The accuracy of tissue
punches was validated using Six6 as aneuroanatomical marker of the SCN (Figure S4A). In view of
the importance of Snap-25 in neurotransmission, surprisingly
few differences in gene expression were observed between
genotypes (Table S3). However, a number of key genes did
show highly significant temporal changes in Bdr mice when
compared to wild-types, including the SCN neuropeptides
Figure 2. The Behavioral and Physiological Response to Light Is Not Altered in Bdr Mice
(A–D) The ability of the circadian activity rhythm to phase shift following a 6 hr phase advance (A) and an acute photic stimulus in the respective night (B) are
comparable in Bdr mice and wild-type controls. The ability for acute suppression of activity (negative masking) by light (C) and the 480 nm light-driven
reduction in pupil area (D) (correlate of melanopsin-driven pupil constriction) are comparable in Bdr mice and wild-type controls. No significant effect of
genotype is observed with any parameter presented. See Table S2 for related p values.
(E and F) Representative ISH of c-fos and Vip in the mid-SCN both before and after a 30 min light pulse (E). Quantification of c-fos expression shows
equivalent levels of light induction in both genotypes (n = 3–4) (F). Data are presented as mean 6 SEM.
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1/substance P (Tac1/Sp) (Table S4), all genes whose protein
products have been variously implicated as SCN output
signals but whose specific function is unclear [22, 23].
To validate the microarray findings, we undertook qPCR
and confirmed that Avp showed a significantly elevated level
of gene expression at ZT6 versus ZT11 in Bdr mice when
compared to wild-type controls (Figure 4A); these findingsFigure 3. The Core Molecular Clock Is Not Altered in Bdr Mice
(A) Representative actograms of mouse running-wheel activity counts (black b
activity patterns in Bdr compared to controls under both DD and 150 LL cycles
Bdr mice; this is reflected in periodogram amplitude values for both DD and L
(B) The free-running period or tau (t) in both DD and LL shows no significant di
a marker of core clock stability, data summarized in Table S2. Data are presen
(C) Representative bioluminescence of organotypic SCN slice culture from thewere also replicated by in situ hybridization (ISH) (Figures 4B
and 4C). Upregulation of Nts from ZT6 to ZT11 in the Bdr SCN
was also confirmed by qRT-PCR (Figure S4E), but changes in
Tac1 fell below significance (Figure S4F). Altered phasing of
Avp protein was then demonstrated by immunohistochemistry
in an independent cohort of animals sampled over 24 hr. The
Avp peak within the SCN of Bdrmutants was at ZT6, whereas
in wild-type mice, expression peaked at ZT10 (Figures 4Dars displayed in 10 min bins) show comparable free-running rhythmicity and
. Increased activity fragmentation compared to wild-types is observed in the
L (Figure 1).
fference (ANOVA, planned comparison) between Bdr and wild-type mice as
ted as mean 6 SEM.
Per2:Luc reporter line either wild-type (blue) or Bdr mutant (red).
Figure 4. Phase Advances of Avp Expression in the SCN and Serum Corticosterone Occurs in Bdr Mice
(A) qRT-PCR from SCN-enriched tissue punches shows advanced peak of Avp expression at ZT6 in Bdr mutants versus wild-type controls (n = 4–5;
ZT6: p = 0.0198, ANOVA, planned comparison).
(B and C) Representative ISH of the mid-SCN from Bdr and control mice using Avp and Vip riboprobes (B). The significantly advanced peak of expression of
Avp at ZT6 in mutants was confirmed by quantification of the ISH signal (n = 3; ZT6: p = 0.003, ANOVA) (C).
(D and E) Immunohistochemistry of Avp over 24 hr confirmed that Avp expression peaked at ZT10 in wild-type SCN (D) but ZT6 inBdrmutants, as quantified
(E) (n = 4; p values: ZT6 = 0.001, ZT10 = 0.002, ZT22 = 0.015, ANOVA).
(F) The circadian timing of serum corticosterone levels were also significantly advanced in Bdr mice compared to wild-type (n = 9; p values: ZT2 = 0.013,
ZT6 = 0.018, ZT10 = 0.016, ZT14 = 0.037, ZT18 = 0.008, ANOVA). Data are presented as mean 6 SEM.
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317and 4E). Microarray analysis and ISH profiling of the SCN
output neuropeptide vasoactive intestinal peptide (Vip) were
comparable between genotypes, however (Figure 4B). Per2:
Luc reporter results were also validated bymicroarray analysis
andqRT-PCRof themolecular clockgenesBmal1,Clock,Per1,
and Per2. None showed any significant differences between
mutant and wild-type mice (Figures S4B–S4D).
The circadian control of glucocorticoid production is
strongly dependent upon the SCN [24]. As a consequence,
we measured plasma corticosterone levels as an additional
assay, along with locomotor behavior, of a peripheral rhythm
under circadian control. Serum corticosterone measurements
were taken across the 24 hr circadian day andwere found to be
significantly advanced in theBdrmicewhen compared towild-
type controls (Figure 4F), correlating with the Bdr phase
advance observed in both SCN Avp expression and wheel-
running activity rhythms.
Discussion
Although no definitive causal links between SNAP-25 muta-
tions and schizophrenia have been proven, there are a consid-
erable number of studies that demonstrate an associationbetween this gene and mental health. For example, synaptic
dysfunction and abnormal neurotransmitter release are
thought to underpin many neuropsychiatric disorders,
including schizophrenia [25, 26]. The Bdr Snap-25 missense
mutation results in increased binding affinities within the
soluble NSF attachment protein receptor (SNARE) complex,
leading to impaired exocytotic vesicle recycling and exocy-
tosis and a reduction in the amplitude of excitatory postsyn-
aptic potentials [3]. Importantly, we have shown previously
that combining theBdrmutation with a prenatal environmental
insult produces enhanced behavioral endophenotypes; the
sensorimotor gating (prepulse inhibition) deficit observed in
mutants was not only exacerbated by prenatal stress but
was also reversible with antipsychotic treatment [4]. Notably,
recent data has shown Bdr-like enhanced SNAP-25 binding
at the striatal synapse in schizophrenia patients [16]. There is
also some indirect evidence that Snap-25 may play a role in
the circadian system; the gene has a rhythmic 24 hr pattern
of expression in the rodent SCN [27], and the effects of Botu-
linium toxin A administration to the SCN in vitro suggests an
important general role for vesicle cycling in clock cell regula-
tion [28]. Finally, there are additional links between SNAP-25
and human cognitive endophenotypes [29] and multiple
Current Biology Vol 22 No 4
318reports of altered SNAP-25 expression in both patients [12, 30]
and mouse models of schizophrenia [31]. Collectively, these
findings support the case that the Bdr mutant provides
a powerful model to study the relationship between circadian
disturbance and synaptic abnormalities in neuropsychiatric
disease.
The results in this study show that the rest and activity cycle
of Bdr mice is phase advanced and markedly fragmented
under a 12:12 LD cycle. However, there appear to be no
defects in the retinal input to the circadian system or in the
capacity of the SCN of the Bdr mouse to generate a normal
circadian rhythm under constant conditions. By contrast, the
24 hr rhythms of both Avp, the best characterized output
peptide of the SCN, and plasma coticosterone are significantly
phased advanced. Collectively, these results suggest that
Snap-25 plays a critical role in the synchronization of central
and peripheral circadian oscillators, coupling molecular
rhythms within the SCN to key output signals that in turn drive
locomotor rhythms of behavior and corticosterone [23]. In the
case of Avp, the fact that both mRNA and protein are phase
advanced suggests that the synaptic defects caused by
mutant Snap-25 must be afferent to the Avp neurons in the
SCN (see graphical abstract for summary). We have shown
previously that the Bdr mutation results in attenuated neu-
rotransmitter release under sustained stimulation [3]. It is
possible, therefore, that the SCN drive on output pathways
under LD conditions diminishes over time, and this may
account for the earlier phase of output signals from the SCN.
Internal desynchrony and circadian misalignment are
seen in many neuropsychiatric diseases and are thought
to involve dysfunction of neurotransmitter systems [1, 32].
Schizophrenia is associated with significant circadian disrup-
tion, the core aspects of which include abnormal phasing,
rest and activity fragmentation, and reduced stability in rest
and activity behavior, as illustrated here by a typical human
activity profile (Figure S2) [1, 17–19]. A recent study has
provided the most comprehensive analysis to date on sleep
in schizophrenia, demonstrating that rest and activity distur-
bance is not an artifact of antipsychotic treatment or lack of
employment [20]. Although direct comparisons between
human and rodent circadian behaviors can be problematic,
many aspects of the circadian disturbance seen in Bdr mice
are similar to that described in patients. In addition, we ob-
served considerable heterogeneity in the rest and activity
phenotype in Bdr mutants ranging from robust and entrained
rhythms to highly irregular circadian profiles. Such interindi-
vidual variation is also seen in patients with schizophrenia
and is normally ascribed to the genetic variability typical of
any human population [1]. That such wide variation is also
found in the circadian phenotype of genetically similar mice,
within a comparable environment, is surprising; this suggests
that a predisposing gene for a neuropsychiatric disorder could
produce either heterogeneity alone or be markedly altered by
very subtle environmental factors.
Another notable similarity between schizophrenia and our
findings in Bdr mice is perturbation of the hypothalamo-
pituitary-adrenal (HPA) axis [33]. Such disruption would not
feed back directly onto the SCN, however, because the SCN
lacks glucocorticoid receptors and is resistant to such periph-
eral rhythm disturbance [34]. Interestingly, abnormal phasing
of glucocorticoids has been reported in patients with schizo-
phrenia [35]. Furthermore, a rodent model of Avp disruption
displays schizophrenic endophenotypes [36], and levels of
both AVP and NTS have been reported to be altered inschizophrenia [37, 38]. Significantly, both of these neuropep-
tides are currently under investigation as potential antipsy-
chotic therapeutic targets [39, 40].
In summary, the Bdr model of schizophrenia-associated
synaptic dysfunction provides the first tangible link between
disruption of rest and activity cycles and the mechanisms
underlying neuropsychiatric disorders. Our results suggest
that the Bdr rest and activity phenotype arises from a dis-
ruption of synaptic connectivity that causes desynchrony
between the SCN and peripheral rhythms. These findings
argue strongly that sleepdisruption in schizophrenia can occur
independently of pharmaceutical or environmental cues. Thus
an abnormality in neurotransmitter signaling that predisposes
an individual to neuropsychiatric illness can have a direct
impact upon sleep/wake timing. As a result, circadian disrup-
tion may serve as a useful endophenotype to assess familial
predisposition to schizophrenia. Furthermore, because of this
mechanistic overlap, it is possible that many of the comorbid
pathologies found in mental health arise directly from or are
exacerbated by disrupted sleep. The stabilization of sleep in
such individuals suggests a means to reduce symptoms and
improve quality of life.
Experimental Procedures
See Supplemental Experimental Procedures for details.
Accession Numbers
Data from the microarray expression analysis are available online under
ArrayExpress accession number E-MEXP-3493.
Supplemental Information
Supplemental Information includes four figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.cub.2011.12.051.
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